INJECTABLE ANTIBIOTIC FORMULATIONS AND USE THEREOF
Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.
1 . A composition, comprising:
(i) a hydrated macrolide;
(ii) at least one suitable solvent; and
(iii) an excipient.
2 . The composition of claim 1 , wherein the solvent is triacetin.
3 . The composition of claim 1 , wherein the macrolide is azithromycin.
4 . The composition of claim 1 , wherein the solvent is present in an amount of about 38.0% w/w.
5 . The composition of claim 1 , further comprising a surfactant.
6 . The composition of claim 5 , wherein the surfactant is castor oil.
7 . The composition of claim 5 , wherein the castor oil comprises kalliphor HS15.
8 . The composition of claim 1 , wherein the solvent is caprylic or caprylic/capric triglycerides.
9 . The composition of claim 8 , wherein the solvent is present in an amount of about 54.0 w/w.
10 . The composition of claim 1 , wherein azithromycin is present in an amount of about 7.0% w/w.
11 . The composition of claim 1 , wherein the solvent is triacetin and caprylic, caprylic or capric triglycerides.
12 . The composition of claim 8 , wherein the triglyceride is a C8 triglyceride.
13 . The composition of claim 11 , wherein the triglyceride is a C8 triglyceride.
14 . The composition of claim 1 , wherein the composition is formulated for injection.
15 . A method of treating an infection in a subject weighing less than about 100 pounds, comprising administering an effective amount of a composition of claim 1 .
16 . The method of claim 15 , further comprising administering an additional antibiotic in combination with the composition of claim 1 .
17 . The method of claim 15 , wherein the subject is a feline.
18 . The method of claim 15 , wherein the composition is administered by injection.
19 . A composition formulated for injection, comprising about 54.0 w/w caprylic triglycerides; about 38.0% w/w triacetin; KALLIPHOR™ HS15; and about 7.0% w/w azithromycin DH.